AZP 2006

Drug Profile

AZP 2006

Alternative Names: AZP2006

Latest Information Update: 09 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AlzProtect; INSERM; University of Lille 2
  • Developer AlzProtect
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Progressive supranuclear palsy
  • No development reported Dementia

Most Recent Events

  • 09 May 2017 No development reported - Preclinical for Dementia in France (unspecified route)
  • 04 May 2017 AZP 2006 receives Orphan Drug status for Progressive supranuclear palsy in USA
  • 26 Mar 2015 The ANSM approves a clinical trial application for AZP 2006 in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top